Substance Use & Harm Reduction

Substance use and harm reduction is the sub-domain where the verification cycle's most encouraging substantive finding (sharp overdose-mortality decline) is paired with persistent demographic-disparity concerns and a nuanced § 280E IRS guidance picture. Philadelphia overdose deaths declined from a 2022 peak of 1,376 to 1,310 in 2023 to 1,045 in 2024 (a 20% decline; PDPH) to 747 preliminary in 2025 through December 23 — on track to be the lowest in nearly a decade (the last sub-1,000 year was 2016 with 907 deaths). Pennsylvania statewide declined from 3,340 in 2024 to 2,178 preliminary in 2025 — a 29% decline year-over-year. The PA Overdose Prevention Program 2025 distributed approximately 800,000 naloxone doses plus 737,000 fentanyl and xylazine test strips and reported approximately 9,500 overdose reversals (January through September 2025). The federal architecture rests on the Controlled Substances Act plus § 856 (the "Crack House Statute"), the DEA Schedule III rescheduling Final Order for state-licensed medical cannabis (signed April 22-23, 2026; effective approximately April 28, 2026), Trump EO 14370 (December 18, 2025), § 280E IRC plus Treasury / IRS press release April 23, 2026, the SUPPORT Act of 2018, the [MAT Act](/paul/campaign/empower/glossary/#mat-act) of 2023, FDA naloxone OTC (March 2023), and [SAMHSA](/paul/campaign/empower/glossary/#samhsa) [OTP](/paul/campaign/empower/glossary/#otp) regulations at 42 C.F.R. Part 8. State framework: PA Medical Marijuana Act (Act 16 of 2016), PA Act 66 of 2021 (Syringe Service Program authorization), PA Act 139 of 2014 (Good Samaritan), PA [PDMP](/paul/campaign/empower/glossary/#pdmp) Acts 191 / 53. Local framework: [DBHIDS](/paul/campaign/empower/glossary/#dbhids) Behavioral Health (PA HealthChoices Behavioral Health single-MCO Philadelphia model); Prevention Point Philadelphia. The Kensington supply chemistry — verified to peer-reviewed source (Hochstatter et al., Drug and Alcohol Dependence, accepted June 2025) — shows the supply known as "demon" (fentanyl-medetomidine ± xylazine) has displaced "tranq" (xylazine-fentanyl), with medetomidine reaching 83% by March 2025 and BTMPS reaching 25%. Demographic disparity persists: 2023 PDPH data showed 15% decrease among non-Hispanic White, only 5% decrease among non-Hispanic Black, and 2% increase among Hispanic people; Pew Charitable Trusts 2025 polling shows declines driven primarily by White rates dropping while Black rates continued rising through 2024.

Legal Architecture

Constitutional foundation

Substance use and harm reduction architecture rests on the Spending Clause (SAMHSA grants; SUPPORT Act block grants), the Commerce Clause (Controlled Substances Act regulatory authority), and the 10th Amendment state police-power grounding for state-level harm-reduction programs. United States v. Safehouse, 985 F.3d 225 (3d Cir. 2021), establishes the principal federal-court interpretation of § 856 as applied to supervised-consumption sites.

Federal statutory layer

Controlled Substances Act plus § 856 ("Crack House Statute"), 21 U.S.C. § 801 et seq., § 856. Statutory stability: HIGH; administrative vulnerability: LOW at federal-statutory level.

DEA Schedule III rescheduling Final Order — signed April 22-23, 2026 by Acting AG Todd Blanche; Federal Register publication and formal effective date approximately April 28, 2026. Statutory stability: HIGH (newly issued); administrative vulnerability: MODERATE — broader cannabis rescheduling hearing for adult-use cannabis begins June 29, 2026 (concludes by July 15).

Trump EO 14370 (December 18, 2025) — directs the Schedule I → III process for state-licensed medical cannabis.

§ 280E Internal Revenue Code plus IRS guidance — Treasury / IRS press release April 23, 2026 ("Treasury, IRS Announce Process for Tax Guidance Following DOJ Final Order on Medical Marijuana Rescheduling"). Three components: (1) prospective relief confirmed — transition rule treats § 280E rescheduling as applying to the full taxable year that includes the Final Order's effective date; for calendar-year filers, all of 2026 is § 280E-exempt for state-licensed medical cannabis activities; (2) apportionment rules for mixed-business operators with allocation methodology unresolved (revenue-based vs. gross-profit-based vs. asset-based); (3) retrospective relief NOT YET COMMITTED — Treasury silent despite explicit DEA encouragement.

SUPPORT Act of 2018, P.L. 115-271. Statutory stability: HIGH.

MAT Act of 2023 — Consolidated Appropriations Act 2023 § 1262; P.L. 117-328. X-waiver elimination effective. Statutory stability: HIGH.

FDA naloxone OTC March 2023 approval. Statutory stability: HIGH; administrative vulnerability: LOW.

SAMHSA OTP regulations, 42 C.F.R. Part 8 (April 2024 revisions effective). Statutory stability: HIGH.

Federal agency layer

DEA administers the CSA plus § 856. HHS / Treasury / IRS administer § 280E guidance. SAMHSA administers OTP regulations plus opioid grant programs. FDA approved naloxone OTC.

State statutory layer

PA Medical Marijuana Act (Act 16 of 2016; 35 P.S. § 10231.101). PA medical cannabis operators qualify as "state licensees" per 21 CFR § 1300.01 definition and are § 280E-exempt prospectively for the 2026 calendar year per the Treasury transition rule. PA does not have an adult-use cannabis program, so PA operators avoid the apportionment-rule complication that affects dual-license operators in adult-use states.

PA Act 66 of 2021 — Syringe Service Program authorization; 35 P.S. § 780-128. Statutory stability: HIGH; county-level implementation partially unverified.

PA Act 139 of 2014 — Drug Overdose Response Immunity / Good Samaritan; 35 P.S. § 780-113.7. Statutory stability: HIGH.

PA Prescription Drug Monitoring Program — Act 191 of 2014 plus Act 53 of 2014, 35 P.S. §§ 872.1-872.41. Statutory stability: HIGH.

Local statutory and local agency layer

DBHIDS Behavioral Health. PA HealthChoices Behavioral Health single-MCO Philadelphia model — a structural feature with cross-domain (D3 Mental Health) implications.

Prevention Point Philadelphia. A 501(c)(3) operating a Syringe Service Program under PA Act 66 of 2021 authorization; established 1991.

Cross-cutting structural features

Feature 1 — Substantial overdose-mortality decline with persistent demographic disparity. Philadelphia 2022 peak 1,376 → 2024 1,045 (-20%) → 2025 preliminary 747. PA statewide 2024 3,340 → 2025 preliminary 2,178 (-29%). PA Overdose Prevention Program 2025: approximately 800,000 naloxone doses; 737,000 test strips; approximately 9,500 reversals (Jan-Sep). Demographic disparity: 2023 PDPH data showed 15% decrease among non-Hispanic White; only 5% decrease among non-Hispanic Black; 2% increase among Hispanic people. Pew Charitable Trusts 2025 polling shows declines driven primarily by White rates dropping while Black rates continued rising through 2024.

Feature 2 — Kensington supply chemistry transition (verified to peer-reviewed source). Per Hochstatter et al. (Drug and Alcohol Dependence, accepted June 2025; PMID 40578053): among 260 samples March 2024-March 2025, fentanyl 98% prevalence (concentration declined 9.6% → 5.3% by mass); xylazine declined 100% → 58%; medetomidine reached 83% by March 2025 (first detected April 2024); BTMPS reached 25% by March 2025 (first detected June 2024); lidocaine plus tetracaine each increased 3% → 63%. Supply known as "demon" (fentanyl-medetomidine ± xylazine) has displaced "tranq" (xylazine-fentanyl). DEA January 2025 data showed medetomidine in 87% of Philadelphia drug samples. PDPH HAN Update June 2025 plus CDC MMWR May 2025 documented suspected medetomidine withdrawal syndrome among Philadelphia fentanyl-exposed patients.

Feature 3 — § 280E IRS guidance creates prospective relief; retrospective relief unresolved. Treasury announced April 23, 2026 that forthcoming guidance will include a transition rule providing prospective relief for the full 2026 calendar year for state-licensed medical cannabis activities. PA medical cannabis operators (Act 16 of 2016) qualify as state licensees and benefit prospectively. PA does not have an adult-use cannabis program, so PA operators avoid the apportionment-rule complication. Retrospective relief has not yet been committed by Treasury despite explicit DEA encouragement, leaving open tax years 2022-2025 at risk; industry has over $1.6 billion in disputed § 280E positions, with Trulieve alone carrying approximately $445 million in potential exposure.

Feature 4 — Causal drivers for the decline. Per researchers including Hochstatter, Lynch, Daskalakis, and Prevention Point: expanded use of long-acting buprenorphine injections (Sublocade monthly, Brixadi weekly/monthly) improving recovery outcomes; buprenorphine prescribers in Philadelphia tripled from approximately 500 to approximately 1,500 (2017-2023) following X-waiver elimination via MAT Act 2023; drug supply chemistry changes (medetomidine plus xylazine non-fatal-overdose mechanisms vs. acute-fentanyl-overdose mechanism, though these substances cause severe withdrawal, slow-healing wounds, and cardiac problems); opioid settlement funding for Narcan and buprenorphine; naloxone bystander administration availability after the FDA OTC approval in March 2023.

Constituent profiles

These profiles illustrate the structural features above. The pathways are drawn from current law applied to documented PA-3 conditions; the people are composites with no claim to identifiable individuals.

Profile 1: Kensington-area constituent on medetomidine-laced supply accessing buprenorphine

Constituent type: an adult Kensington-area resident with active opioid use disorder, exposed to "demon" (fentanyl-medetomidine ± xylazine) supply, accessing buprenorphine through the MAT Act 2023-expanded Philadelphia prescriber base.

Pathway through the institutional system. Clinical encounter with primary care, FQHC, or DBHIDS-network behavioral-health provider. MAT Act 2023 X-waiver elimination → expanded Philadelphia buprenorphine prescriber base (approximately 1,500 in 2023 vs. approximately 500 in 2017) → Sublocade or Brixadi long-acting injection → ongoing treatment plus harm-reduction overlay. Kensington supply March 2025: fentanyl 98%, medetomidine 83%, xylazine 58%, BTMPS 25% per Hochstatter et al. PA Overdose Prevention Program 2025: approximately 800,000 naloxone doses; approximately 9,500 reversals (Jan-Sep 2025); Philadelphia overdose deaths 2025 preliminary 747 (down from the 1,376 peak in 2022).

Outcome. The constituent has substantially expanded access to buprenorphine treatment; faces medetomidine-withdrawal-syndrome risk and slow-healing wound burden; mortality risk reduced compared to the acute-fentanyl-overdose mechanism.

Profile 2: PA medical cannabis patient post-DEA Schedule III and § 280E exemption

Constituent type: a PA medical-cannabis cardholder accessing medical cannabis through a PA-3 dispensary operating under the PA Medical Marijuana Act (Act 16 of 2016).

Pathway through the institutional system. DEA Schedule III Final Order signed April 22-23, 2026; Treasury / IRS § 280E guidance April 23, 2026 confirming prospective relief for the full 2026 calendar year. DEA Final Order → Treasury transition rule → PA dispensary operator becomes § 280E-exempt prospectively for 2026 → operational economics improve (deductions previously disallowed under § 280E now allowed) → potential pricing or access effects downstream. Industry has over $1.6 billion in disputed § 280E positions; Trulieve alone approximately $445 million. PA does not have an adult-use program (avoiding the apportionment-rule complication); retrospective relief has not yet been committed by Treasury for open tax years 2022-2025.

Outcome. The patient continues to access medical cannabis through a PA-3 dispensary; the dispensary operator's economics improve prospectively in 2026; downstream pricing or access effects are speculative at the patient-experience level.

Profile 3: Kensington Wellness Court participant

Constituent type: an adult arrested in Kensington in 2025 by Philadelphia police on substance-related charges, brought into the Kensington Wellness Court program (launched January 2025 by Mayor Parker).

Pathway through the institutional system. Arrest plus Wellness Court intake → treatment option (vs. prosecution) → outcome distribution. 217 arrested; 72 accepted treatment option; 10 completed; 1 of 10 later died of overdose; two-thirds of those who agreed have bench warrants. Annual budget $2.7 million; first dedicated director Eleni Belisonzi named October 2025. Pew Charitable Trusts 2025 polling: 28% rate Mayor Parker's drug-crisis handling good or excellent vs. 39% not very good or not at all good; Kensington-specific actions 46% effective vs. 39% not very or not at all effective.

Outcome. The person enters Wellness Court. The statistical outcome distribution skews toward bench-warrant non-completion ("we've literally had clients that, when the transport pulls up to a red light, have exited the car and ran" — Chief Defender Hudson). Researcher consensus suggests compulsory-treatment models do not reduce drug use.

Conversational note

But the demographic disparity is real and persistent. 2023 PDPH data showed 15% decrease among non-Hispanic White, only 5% decrease among non-Hispanic Black, and 2% increase among Hispanic people. Pew 2025 polling shows declines driven primarily by White rates dropping while Black rates continued rising through 2024. The mechanism appears to be unequal access to long-acting buprenorphine treatments (Sublocade monthly, Brixadi weekly/monthly) and to harm-reduction infrastructure. The Kensington supply chemistry — verified to Hochstatter et al. peer-reviewed source — shows the supply known as "demon" (fentanyl-medetomidine ± xylazine) has displaced "tranq" (xylazine-fentanyl), with medetomidine reaching 83% of samples by March 2025 and BTMPS reaching 25%. These substances reduce fatal-overdose mechanisms but cause severe withdrawal, slow-healing wounds, and cardiac problems.

The § 280E IRS guidance picture is consequential for PA-3 cannabis-dispensary operators and substantively material for the broader cannabis-policy posture. Treasury announced April 23, 2026 that forthcoming guidance will include a transition rule providing prospective relief for the full 2026 calendar year for state-licensed medical cannabis activities. PA medical cannabis operators (Act 16 of 2016) qualify as state licensees per 21 CFR § 1300.01 and benefit prospectively. PA does not have an adult-use cannabis program, so PA operators avoid the apportionment-rule complication facing dual-license operators in adult-use states. Retrospective relief has not yet been committed by Treasury despite explicit DEA encouragement, leaving open tax years 2022-2025 at risk; industry has over $1.6 billion in disputed § 280E positions, with Trulieve alone carrying approximately $445 million in potential exposure.

The Safehouse procedural posture continues under § 856 federal statutory bar. The 2021 3d Cir. decision (Bibas, J., 2-1) holding the supervised-consumption site would violate § 856 stands; SCOTUS denied cert October 2021. April 4, 2024 Judge McHugh dismissed Safehouse's RFRA counterclaim; June 2024 Safehouse filed Notice of Appeal to 3d Cir. (RFRA dimension); 3d Cir. status pending. PA local context: September 2023 Philadelphia City Council 9-of-10-district zoning ban (overrode Mayor Kenney veto); Mayor Parker (January 2024) has not publicly supported.

The Kensington Wellness Court (Mayor Parker; January 2025 launch) operates as a substantive PA-3 institutional response with measurable outcomes: 217 arrested; 72 accepted; 10 completed; 1 of 10 later died of overdose; two-thirds bench warrants. Pew 2025 polling: 28% rate Mayor Parker's drug-crisis handling good or excellent vs. 39% not very good or not at all good. Researcher consensus suggests compulsory-treatment models do not reduce drug use.

The MAT Act 2023 X-waiver elimination continues operative; per PDPH data, Philadelphia buprenorphine prescribers nearly tripled from 2017 to 2023, reaching approximately 1,500. SAMHSA OTP regulations at 42 C.F.R. Part 8 continue operative; methadone OTP capacity in PA-3 is partially unverified. DBHIDS single-MCO behavioral-health model continues operative as a structural feature of PA-3 with cross-domain implications for D3 Mental Health.

The aggregate signal is that the PA-3 substance-use landscape shows substantial mortality reduction in the verification window, with persistent racial disparities that point to differential access to evidence-based treatment as the operative mechanism, supply-chemistry transitions that reduce acute-overdose mortality but introduce different morbidity (withdrawal, wounds, cardiac), and a federal § 280E policy posture that materially benefits PA medical cannabis operators prospectively while leaving retrospective relief unresolved.

Geography & representation

Data provenance. Philadelphia overdose deaths trajectory (2022 peak 1,376; 2024 1,045; 2025 preliminary 747 through December 23) is from PDPH. PA statewide 2024 figure 3,340 and 2025 preliminary 2,178 (-29%) are from PA Department of Drug and Alcohol Programs. PA Overdose Prevention Program scale (approximately 800,000 naloxone doses plus 737,000 test strips plus approximately 9,500 reversals in Jan-Sep 2025; over 1.3 million naloxone doses distributed in PA since 2017) is from PA DDAP. Demographic disparity figures (2023 PDPH: 15% / 5% / +2% by race/ethnicity) are from PDPH; Pew Charitable Trusts 2025 polling confirms continued Black/Hispanic rising rates. Kensington supply chemistry (260 samples March 2024-March 2025; fentanyl 98%; medetomidine 83% by March 2025; BTMPS 25%; xylazine 58%; "demon" displacing "tranq") is verified to Hochstatter et al., Drug and Alcohol Dependence, accepted June 2025, PMID 40578053. DEA January 2025 data showed medetomidine in 87% of Philadelphia drug samples. § 280E IRS guidance specifics (Treasury press release April 23, 2026; prospective relief for full 2026 calendar year; apportionment rules pending; retrospective relief not yet committed; over $1.6 billion industry-wide disputed positions; Trulieve $445M) are from Treasury / IRS press release plus Foley Hoag, Bradley, Canna Law Blog, and Current Federal Tax Developments practitioner analyses. Kensington Wellness Court data (217 arrested; 72 accepted; 10 completed; 1 of 10 OD'd; two-thirds bench warrants; $2.7M annual budget; Eleni Belisonzi named director October 2025; Pew 2025 polling on Mayor Parker's handling: 28% good/excellent vs. 39% not very good) is from Billy Penn / WHYY reporting.

PA-3 statistical profile. Philadelphia is one of CDC's directly-funded jurisdictions for HIV prevention; PDPH operates the AACO Philadelphia EMA infrastructure (treated in the Communicable Disease Control sub-domain). The PA-3 OD-mortality population shows substantial recent decline in absolute terms with concentration in Kensington area (within North/Northwest Philadelphia Core periphery). 10,000+ patients with opioid use disorder are seen annually in Philadelphia EDs.

Geographic variation.

North/Northwest Philadelphia Core. Kensington area (within North/Northwest Philadelphia Core periphery) carries the heaviest concentration of OD mortality and active substance use in PA-3; Prevention Point Philadelphia operates here.
West Philadelphia Core. Substantial OUD population accessing FQHC plus buprenorphine pathways (cross-reference the Health Access sub-domain); lower OD mortality concentration than Kensington area.
Northwest Philadelphia. Lower OD mortality concentration; Wissahickon Valley residential mix.
South/Southwest Philadelphia. Mixed pattern; tract-level disaggregation not located.

Specific tract-level overdose mortality figures for PA-3 sub-areas in 2025 are partially unverified at the sub-domain level; the 1,045 (2024) and 747 (2025 preliminary) figures are city-level. Sub-area patterns are presented as structural inference informed by Kensington-area concentration.

Pathway tracing.

§ 280E IRS guidance → PA medical cannabis operator pathway. DEA Schedule III rescheduling for state-licensed medical cannabis (April 22-28, 2026) → Treasury / IRS guidance April 23, 2026 → forthcoming transition rule → calendar-year 2026 § 280E exemption for state-licensed medical cannabis activities → PA medical cannabis operators (Act 16 of 2016) qualify and benefit prospectively. Pathway breakdown points: retrospective relief not yet committed by Treasury (open tax years 2022-2025 at risk); apportionment-rule complication does not affect PA (no adult-use program); industry has over $1.6 billion in disputed § 280E positions.
MAT Act 2023 X-waiver elimination → buprenorphine prescriber expansion. Federal X-waiver elimination effective → PA buprenorphine prescriber base expands → per PDPH data, Philadelphia buprenorphine prescribers nearly tripled from 2017 to 2023 (approximately 500 to approximately 1,500). Continues operative as durable structural reform.
FDA naloxone OTC plus PA Overdose Prevention Program. FDA OTC approval (March 2023) → PA Overdose Prevention Program "hub-and-spoke" model → 2025 full-year approximately 800,000 doses naloxone distributed; 737,000 fentanyl and xylazine test strips; approximately 9,500 overdose reversals (Jan-Sep 2025). Over 1.3 million naloxone doses distributed in PA since 2017.
PA Act 66 of 2021 SSP pathway. Statutory authorization → Prevention Point Philadelphia plus county SSP implementation → PA-3 syringe service access. Pathway breakdown points: county-level implementation partially unverified.
§ 856 plus Safehouse litigation. CSA § 856 federal statutory bar on supervised consumption → 2021 3d Cir. decision (Bibas, J., 2-1) holding the supervised-consumption site would violate § 856 → SCOTUS denied cert October 2021 → April 4, 2024 Judge McHugh dismissed Safehouse RFRA counterclaim → June 2024 Safehouse Notice of Appeal to 3d Cir. (RFRA dimension) → 3d Cir. status pending. PA local context: September 2023 Philadelphia City Council 9-of-10-district zoning ban (overrode Mayor Kenney veto); Mayor Parker has not publicly supported.
DBHIDS single-MCO behavioral-health pathway. PA HealthChoices Behavioral Health single-MCO model in Philadelphia → DBHIDS administers → SUD plus behavioral-health treatment continuity → 10,000+ patients with opioid use disorder seen annually in Philadelphia EDs. Cross-reference D3 Mental Health.
Kensington Wellness Court (Mayor Parker; January 2025 launch). Police arrest in Kensington → Wellness Court → treatment option (vs. prosecution) → 217 arrested; 72 accepted; 10 completed; 1 of 10 later died of overdose; two-thirds bench warrants. Annual budget $2.7 million; first dedicated director Eleni Belisonzi named October 2025.

Representation question. PA-3 constituents affected by substance use are promised by the federal framework: CSA plus § 856 federal scheduling and supervised-consumption-site framework; DEA Schedule III rescheduling for state-licensed medical cannabis (Final Order April 22-28, 2026); § 280E IRC plus Treasury / IRS guidance for cannabis operators; SUPPORT Act SUD treatment infrastructure; MAT Act 2023 X-waiver elimination; FDA naloxone OTC; SAMHSA OTP regulations. The PA framework adds the PA Medical Marijuana Act (Act 16 of 2016), PA Act 66 of 2021 (SSP authorization), PA Act 139 of 2014 (Good Samaritan), and the PA PDMP. Locally, DBHIDS Behavioral Health single-MCO and Prevention Point Philadelphia operate. As of mid-2026, PA-3 constituents face substantial overdose-mortality decline (Philadelphia 2025 preliminary 747 vs. 2022 peak 1,376; PA statewide 29% decline 2024 → 2025); approximately 800,000 naloxone doses distributed in PA in 2025; approximately 9,500 reversals (Jan-Sep); buprenorphine prescriber base substantially expanded post-MAT Act 2023; Kensington supply chemistry transitioning to "demon" with non-fatal-overdose-mechanism profile but new morbidity burden; Wellness Court operative with 217-arrest / 72-accepted / 10-completed / 1-OD-death distribution; PA medical cannabis operators § 280E-exempt prospectively for 2026; retrospective relief not yet committed; and persistent demographic disparity in OD mortality (Black rates rising while White rates dropping). The mortality decline is the most encouraging finding in the verification cycle; the persistent racial disparity is the most consequential gap finding; the § 280E IRS guidance is a structural relief for PA medical cannabis operators prospectively but leaves retrospective relief unresolved.

Gap analysis

Gap 1 — CSA § 856 federal supervised-consumption block continuing (G2-SD7-01). Safehouse June 2024 3d Cir. appeal pending; September 2023 Philadelphia City Council 9-of-10-district zoning ban (overrode Mayor Kenney veto); Mayor Parker not publicly supportive.

Gap 2 — Recent OD mortality decline trajectory (G2-SD7-02). Updated: Philadelphia 2024 1,045 and 2025 preliminary 747 (through December 23) figures available; PA statewide 29% decline 2024 → 2025; demographic disparity persists.

Gap 3 — Kensington supply chemistry transition (G2-SD7-03). Verified to peer-reviewed source. Hochstatter et al. measurements match the figures exactly (medetomidine 83%; BTMPS 25%); supply known as "demon" has displaced "tranq."

Gap 4 — Prevention Point operating authority under PA Act 66 of 2021 (G2-SD7-04). Statutory framework confirmed; county-level implementation partially unverified.

Gap 5 — DEA Schedule III licensee 60-day priority window (G2-SD7-05). Cross-reference D4 cycle; window data due approximately late June 2026 (after the verification cycle).

Gap 6 — Race-disparate overdose mortality mechanism (G2-SD7-06). Reinforced. Pew 2025 polling and 2023 PDPH demographic breakdown confirm continued Black/Hispanic disparity in OD mortality outcomes despite overall decline.

Gap 7 — DBHIDS single-MCO BH straddling SUD (G2-SD7-07). Confirmed; structural feature with cross-domain (D3 Mental Health) implications.

Gap 8 — § 280E retrospective relief guidance pending IRS (G2-SD7-08). Substantively updated. Treasury announced framework April 23, 2026; prospective relief confirmed for full 2026 calendar year for state-licensed medical cannabis operations; apportionment rules pending for mixed-business operators; retrospective relief NOT YET COMMITTED by Treasury. PA medical cannabis operators (Act 16 of 2016) qualify as state licensees and are § 280E-exempt prospectively for 2026; PA operators avoid the apportionment-rule complication.

Gap 9 — Mayor Parker / Kensington Wellness Court structural framing (G2-SD7-09). Updated. 217 arrested / 72 accepted / 10 completed / 1 of 10 OD'd; two-thirds bench warrants; 28% Pew approval; structural-effectiveness doubts.